New Radiochemical Lab to Support Next-Gen Cancer Treatment
At the official opening of LARS (From L-R): Professor Paul Donnelly, Richard Robson Chair of Chemistry, Professor Moira O’Bryan, Dean of Science, Professor Mark Cassidy, Deputy Vice-Chancellor (Research), University of Melbourne and Dr James Glasgow, CEO of Cyclotek The University of Melbourne and radiopharmaceutical manufacturer Cyclotek today opened the Laboratory for Advanced Radiochemical Science […]
Cyclotek Awarded CRC-P Round 16 Grant to Advance Nanobody-Based Theranostic Platform for Cancer
Cyclotek, Australia’s leading radiopharmaceutical CDMO, is proud to announce its successful application for a Cooperative Research Centres Projects (CRC-P) Round 16 grant, awarded by the Australian Government to support collaborative industry-led research that delivers commercial outcomes.
Cyclotek Enables First in Human Company-Sponsored Trial with Terbium-161 Radiopharmaceutical in Australia
Cyclotek is excited to announce a contract development and manufacturing agreement with Radiopharm Theranostics, to support the company’s first-in-human, Phase 1 trial of RAD 402, a novel terbium-161 (¹⁶¹Tb) radiolabelled monoclonal antibody for the treatment of prostate cancer. Cyclotek, a leading Contract Development and Manufacturing Organization (CDMO) in radiopharmaceuticals, has been supporting commercially sponsored clinical […]
Cyclotek and the University of Melbourne sign Strategic Partnership Agreement
Radiopharmaceutical manufacturer Cyclotek and the University of Melbourne have signed a Strategic Partnership Agreement to set up a new research facility to support the advancement of cutting-edge cancer targeting technology. The agreement is aimed at facilitating workforce development and the translation of radiopharmaceutical innovation to the commercial market. The radiopharmaceutical research and development laboratory […]
Cyclotek lends a hand in PSMA-PET in Active Surveillance for Ca Prostate
Cyclotek is collaborating with Whitten Foundation-led research to pave the way for better detection and identification of high-grade cancer in the prostate by using a PSMA PET scan in those patients deemed suitable for Active Surveillance (AS). The supply of GMP approved prostate-specific radiopharmaceutical (18F-DCFPyL) is being provided by Cyclotek to clinically localise the sites […]
Cyclotek supports Macquarie University’s Research Studies in Motor Neuron Disease (MND)
In collaboration with Macquarie University and Life Molecular Imaging (LMI), Cyclotek is pleased to announce our participation in the study to determine the safety and potential effective dose of the novel therapy, 3K3A-APC in patients with Amyotrophic Lateral Sclerosis (ALS). The 18F-FEMPA, a novel radiopharmaceutical developed by LMI and produced by Cyclotek, is being used […]
Neuroinflammation as a Mechanism, Biomarker, and Therapeutic Target in Degenerative Brain Disorders
Immune-responsive cells of the brain – namely microglia and astrocytes – activate in response to brain injury or pathogens. This activation leads to a local neuroinflammatory response that serves to isolate and protect the tissue, remove the noxious agent, and promote recovery. However, while beneficial in the short term, the chronic release of pro-inflammatory chemicals […]
ASAN Medical Centre and Duchembio, Korea, licence DAT PET tracer for Parkinson’s to Cyclotek
ASAN Medical Center and Duchembio Co. Ltd. announce Strategic Partnership with Cyclotek for Exclusive Licensing of [18F]FP-CIT in Australia and New Zealand SEOUL/MELBOURNE, June 30, 2017 – The ASAN Medical Center (AMC) and Duchembio Co. Ltd. (DCB) today announced that the parties have entered into a strategic partnership and licensing agreement with Cyclotek (Aust) Pty […]
Prostate tracers [18F]DCFPyL and [68Ga]PSMA comparison
Paper compares [68Ga] and [18F] PSMA labeled tracers
Cyclotek supports pilot PET clinical trial in multiple sclerosis (MS)
F18-FEMPA is a novel radiotracer owned by Piramal Imaging and produced under license by Cyclotek